Brainstorm readies phase III trial for NurOwn stem cell treatment for ALS

Brainstorm Cell Therapeutics (NSDQ:BCLI) said today that it’s preparing for a phase III trial of its NurOwn stem cell treatment, after meeting with the FDA about a biologic license application. The company is developing adult stem cell therapies derived from autologous bone marrow cells to treat neurodegenerative diseases, such as ALS.

Hackensack, N.J.-based Brainstorm is planning a randomized, double-blind, multi-dose phase III trial at multiple sites across the U.S. and in Israel. The trial is slated to enroll patients in the 2nd quarter of next year.

Get the full story at our sister site, Drug Delivery Business News.

The post Brainstorm readies phase III trial for NurOwn stem cell treatment for ALS appeared first on MassDevice.

from MassDevice http://ift.tt/2hMC6sQ